<DOC>
	<DOCNO>NCT02805790</DOCNO>
	<brief_summary>This Phase 2 , randomize , double-blind , placebo-controlled crossover study enroll 36 subject ( anticipate ) genetically confirm mitochondrial disease complete participation SPIMM-201 ( MMPOWER ) study . Subjects randomize ( 1:1 ) one two sequence group : 4-weeks treatment 40 mg elamipretide administer daily subcutaneously Treatment Period 1 follow 4-weeks treatment placebo administer daily subcutaneously Treatment Period 2 ( separate 4-week washout period ) , vice versa</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability , Efficacy Subcutaneous Injections Elamipretide ( MTP-131 ) Subjects With Genetically Confirmed Mitochondrial Disease Previously Treated Stealth BioTherapeutics SPIMM-201 Study</brief_title>
	<detailed_description />
	<mesh_term>Mitochondrial Diseases</mesh_term>
	<criteria>Subject complete participation SPIMM201 study without significant protocol deviation would suggest subject may able complete study requirement opinion Sponsor Subject must reside North America duration study Subject receive study drug SPIMM201 study within 3 week prior Screening Women childbearing potential must agree use 1 method birth control specify protocol date sign ICF two month last dose study drug Subject stable ( unchanged constant ) medication ( include overthe counter treatment , vitamin , supplement ) least 1 month prior Baseline Visit Subject prior current medical condition , judgment Investigator , would prevent subject safely participate and/or complete study requirement ( i.e . unstable angina recent myocardial infarction ) Subject receive investigational compound and/or participate another interventional clinical study within 30 day prior Baseline Visit concurrently enrol noninterventional research type judge scientifically medically incompatible study deem Investigator consultation Sponsor Subject experience adverse reaction study drug SPIMM201 study contraindicate treatment elamipretide opinion Investigator and/or Sponsor Female subject pregnant , plan become pregnant , lactate Subject undergone inpatient hospitalization within 1 month prior Screening Visit likely need inpatient hospitalization surgical procedure course study Subject creatinine clearance ≤30 mL/min calculate Cockcroft Gault equation Subject QTc elongation define QTc &gt; 450 msec male subject &gt; 480msec female subject . Note : At initial electrocardiogram ( ECG ) , QTc exceed parameter , ECG may repeat 2 time , average 3 QTc value use determine subject eligibility Subject uncontrolled hypertension judgment Investigator ( e.g . elevate &gt; 160 mmHg systolic &gt; 100 mmHg diastolic despite appropriate treatment two consecutive reading ) Subject history clinically significant hypersensitivity allergy excipients contain study drug Subject history active alcoholism drug addiction year Screening Visit</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Primary Mitochondrial Disease</keyword>
	<keyword>Mitochondrial Myopathy</keyword>
	<keyword>Elamipretide</keyword>
	<keyword>MTP-131</keyword>
	<keyword>Bendavia™</keyword>
</DOC>